FcRn inhibitors:a novel option for the treatment of myasthenia gravis  

作　　者：Li-Na Zhu Hai-Man Hou Sai Wang Shuang Zhang Ge-Ge Wang Zi-Yan Guo Jun Wu 

机构地区：[1]Department of Neurology,The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan Province,China

出　　处：《Neural Regeneration Research》2023年第8期1637-1644,共8页中国神经再生研究（英文版）

基　　金：supported by the National Natural Science Foundation of China,No.U1604181;the Joint Project of Medical Science and Technology Research Program of Henon Province,No.LHGJ20190078;Henan Medical Education Research Project,No.Wjlx2020531;Henan Province Key R&D and Promotion Special Project(Science and Technology Tackle),No.212102310834(all to JW)。

摘　　要：Myasthenia gravis is an acquired,humoral immunity-mediated autoimmune disease characterized by the production of autoantibodies that impair synaptic transmission at the neuromuscular junction.The intervention-mediated clearance of immunoglobulin G(IgG)was shown to be effective in controlling the progression of the disease.The neonatal Fc receptor(FcRn)plays a key role in prolonging the serum half-life of IgG.Antagonizing FcRn to prevent its binding to IgG can accelerate the catabolism of the latter,resulting in decreased levels of IgG,including pathogenic autoantibodies,thereby achieving a therapeutic effect.In this review,we detail the substantial research progress,both basic and clinical,relating to the use of FcRn inhibitors in the treatment of myasthenia gravis.

关 键 词：batoclimab clinical trial efgartigimod FCRN FcRn inhibitors immunoglobulin G(IgG) myasthenia gravis nipocalimab rozanolixizumab 

分 类 号：R746.1[医药卫生—神经病学与精神病学]